Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug action on ribonucleotide reductase.

J G Cory, G L Carter

    Advances in Enzyme Regulation
    |January 1, 1985
    PubMed
    Summary

    Ribonucleotide reductase is crucial for DNA synthesis and a target for cancer drugs. Inhibiting its subunits synergistically halts tumor cell growth and increases cytotoxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Reduced prevalence of pain and distress during 4 years of screening with QUICATOUCH in Australian oncology patients.

    European journal of cancer care·2017
    Same author

    Mental health and other clinical correlates of euthanasia attitudes in an Australian outpatient cancer population.

    Psycho-oncology·2006
    Same author

    Lithium toxicity: an iatrogenic problem in susceptible individuals.

    The Australian and New Zealand journal of psychiatry·2002
    Same author

    Augmentation of apoptosis responses in p53-deficient L1210 cells by compounds directed at blocking NFkappaB activation.

    Anticancer research·2002
    Same author

    What people say about their general practitioners' treatment of anxiety and depression.

    The Medical journal of Australia·2001
    Same author

    Comparison of the properties of human breast cancer cells: MCF-7 and MCF-7 cells selected for resistance to etoposide.

    Advances in enzyme regulation·2001

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Cancer Research

    Background:

    • Ribonucleotide reductase (RR) is essential for DNA synthesis, catalyzing a rate-limiting step.
    • RR is a key metabolic target for developing antitumor agents.
    • Inhibitors targeting RR have been extensively studied.

    Purpose of the Study:

    • To investigate the kinetics and inhibition of ribonucleotide reductase.
    • To explore the potential of specific RR inhibitors as antitumor agents.
    • To evaluate the synergistic effects of combined RR subunit inhibition.

    Main Methods:

    • Theoretical calculations of enzyme kinetics.
    • Experimental determination of DNA polymerase activity.
    • Studies using intact tumor cells (L1210).

    Main Results:

    • A 50% decrease in RR activity leads to a >75% decrease in DNA polymerase activity.
    • Structural requirements for RR inhibition are stringent.
    • Combined inhibition of RR subunits demonstrates synergistic effects on cell growth and cytotoxicity.

    Conclusions:

    • Ribonucleotide reductase is a critical target for cancer therapy.
    • Specific inhibition of RR subunits can lead to potent antitumor effects.
    • Combination therapy targeting both RR subunits offers a promising strategy for enhanced cancer treatment.

    Related Experiment Videos